Despite an overall decline in prescribed opioid use in Canada over the past decade, a recent study by researchers from the School of Pharmacy at the University of Waterloo, found that people in poorer areas receive three times the prescriptions for opioids than those in wealthier areas.
The fourth issue of ACS Medicinal Chemistry Letters Journal features art compiled by University of Waterloo School of Pharmacy PhD student Ahmed Hefny for their research, Novel Phenoselenazines as Amyloid-β Aggregation Inhibitors.
A new mathematical model developed at the University of Waterloo School of Pharmacy can determine a baby’s overall drug exposure when their mother is taking medication.
Researchers from Waterloo Pharmacy have developed a new technology that can hold an entire course of antibiotics in one tiny dose and deliver on demand just the right amount of medication that a particular patient needs to fight an infection.
Waterloo PhD candidate, Mira Maximos, investigates sex, gender and the regulation of prescription drugs
Canada will not reach the original World Health Organization's (WHO) target of eliminating the Hepatitis C virus (HCV) by 2030 and lags in comparison to other developed countries, a new study led by researchers at the University of Waterloo has found.
Nasal-administered naloxone is cost-effective and could help reduce the number of opioid-related fatalities compared to the current publicly funded intermuscular version, a new study has found.
Waterloo’s clinical associate professor, Dr. Tejal Patel, has teamed up with QRxDigital to include QR codes on medication bottles that link to an instructional video that patients can view at home.
University of Waterloo pharmacy associate professor Emmanuel Ho has developed a novel nanomedicine loaded with genetic material called small interfering RNAs (siRNA) to fight human immunodeficiency virus (HIV) using gene therapy. These siRNAs regulate which genes or proteins are turned on or off in our cells and showed a 73 per cent reduction in HIV replication.
Respiratory Syncytial Virus (RSV) is a common virus that seriously affects vulnerable populations such as infants, young children and older adults. Dr. Wasem Alsabbagh, associate professor at the University of Waterloo School of Pharmacy, answers frequently asked questions about RSV.